Polarean Imaging

Executive Summary

Polarean Imaging is a US-based medical imaging company pioneering hyperpolarized xenon-129 MRI technology for non-invasive, radiation-free lung function assessment. Its FDA-approved drug-device combination product, XENOVIEW™, enables visualization of lung ventilation in a single breath-hold, addressing a critical unmet need in pulmonary diagnostics. The platform has the potential to transform the management of chronic respiratory diseases such as COPD and asthma, where current imaging modalities lack functional sensitivity. Despite a strong technological moat and regulatory validation, commercial adoption faces hurdles including limited reimbursement coverage, the need for specialized equipment, and market education. Polarean's focus on expanding clinical evidence and securing payer partnerships will be key to driving uptake and revenue growth. The company represents a niche but high-impact opportunity in precision lung imaging, with a clear pathway to value creation if execution milestones are met.

Upcoming Catalysts (preview)

• Q3 2026Expanded reimbursement coverage from CMS or private payers60% success
• TBDPublication of pivotal trial results in new indications (e.g., COVID-19 long-term effects)50% success
• Q4 2026Strategic partnership or distribution agreement with a larger imaging or pharma company40% success